Hansa Biopharma: Negative anti-GBM Phase III Readout - Redeye

Redeye comments on the topline data from the phase III study of imlifidase in anti-GBM disease. There was no difference between the treatment and control arm. We remove the anti-GBM indication from our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1143730/hansa-biopharma-negative-anti-gbm-phase-iii-readout?utm_source=finwire&utm_medium=RSS